智通财经APP获悉，中泰证券发布研报称，医药作为兼具科技和消费属性的板块，在市场行情的轮动中 将持续呈现结构性行情，关于科技属性，创新药板块已经历了过去一年来的急涨后回调，相比2025年年 初的位置，普遍标的估值合理，因此建议关注所在细分行业(优选小核酸、体内CAR、ADC、二代IO、 protac等)及公司本身基本面有边际变化且持续性有望兑现的标的，医药/医疗AI+则是近期热度持续高涨 的新方向，除关注赛道龙头外，建议关注主营业务非医药/医疗AI+相关，但积极拥抱相关技术并预期能 够中短期内兑现估值弹性的标的。 中泰证券主要观点如下： 把握医药结构性行情，持续关注医药/医疗AI+，基本面有积极变化的轻筹码标的。 本周沪深300上涨0.36%，医药生物下滑0.81%，处于31个一级子行业第21位，本周医疗服务上涨 0.22%，化学制药、生物制品、医疗器械、中药、医药商业分别下跌0.54%、0.89%、1.07%、1.75%、 2.68%。本周医药行情分明显，AI医疗、前期回调明显的小核酸相关标的、基本面有边际变化且机构筹 码较轻的部分个股表现亮眼。 该行认为医药作为兼具科技和消费属性的板块，在市场行情的轮动中 ...

华人健康公告称，本次上市流通的限售股份为首次公开发行前已发行的限售股份，申请解除限售的股东 共6户，解除限售股份数量为250,837,347股，占总股本比例62.71%，上市流通日期为2026年3月2日。解 除限售后，限售条件流通股占比降至42.76%，无限售条件流通股占比升至57.24%。保荐人华泰联合证 券认为本次限售股份上市流通符合相关要求，申请解除股份限售的股东已严格履行承诺。 ...

1月16日，国发股份发布2025年度业绩预告称，预计全年实现营业收入约3.3亿元，扣除无关收入后仍为 3.3亿元；预计归母净亏损约8500万元，同比减亏900万元，减亏幅度10%；扣非归母净亏损约8550万 元，同比减亏450万元。业绩预亏主要受子公司高盛生物盈利转亏、制药板块营收下滑及商誉减值计提 影响。 2月24日，国发股份（600538.SH）发布公告，针对上海证券交易所关于公司2025年度业绩预告的问询 函作出详细回复，就营业收入合规性、医药流通增速合理性及商誉减值等核心问题逐一说明。公司明确 营收扣除符合监管规定，医药流通增长具备业务支撑，同时披露拟对全资子公司广州高盛生物计提约 6200万元商誉减值。 上交所对公司医药流通业务增速高于行业水平提出质疑，要求详细说明增长合理性。国发股份从业务结 构、物流模式、区域市场、季度分布四方面进行了回应。 国发股份表示，公司医药流通收入以医院销售为主，占比达86%，快批、零售等板块有所下滑；物流以 自有仓库与配送体系为主，仅单一医院医疗器械合作使用第三方仓储，收入确认政策未发生变更，以客 户签收或实际使用为依据。 从区域来看，公司核心市场北部湾三市药品市场增速 ...

有投资者在互动平台向英特集团提问："公司是否有负责中药饮片的事业部或分公司？贵司如何结合国 家对中药的积极政策，做好妥善布局！谢谢。" 来源：市场资讯 针对上述提问，英特集团回应称："您好！公司设有中药事业部，高度重视国家中医药产业相关政策， 公司将持续密切跟踪政策动态，积极把握行业发展机遇，稳妥推进中药销售业务。感谢您的关注。" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600538 证券简称：国发股份 公告编号：临2026-005 北海国发川山生物股份有限公司 关于上海证券交易所对公司业绩预告相关事项问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 公司预计2025年度实现营业收入约3.3亿元，扣除与主营业务无关的业务收入和不具备商业实质的营业 收入仍为3.3亿元；归属于母公司所有者的净利润-0.85亿元。请公司补充披露：（1）根据《上海证券交 易所上市公司自律监管指南第2号一一业务办理》附件第七号《财务类退市指标：营业收入扣除》有关 规定，说明营业收入扣除相关情况，包括但不限于扣除项目、金额、相关业务开展情况及扣除原因等， 并逐项核实并说明是否存在其他应当扣除尚无扣除的情况；（2）按主要产品类别或业务板块，列示 2025年度预计实现营业收入的具体金额、占比、毛利率及同比变动情况，并说明主要影响因素；（3） 各业务板块前五大客户情况，包括客户名称、合同签订时间、合作期限、是否新增客户或关联方、销售 内容、销售金额、应 ...

Core Viewpoint - The company is experiencing significant financial challenges, with declining profits and a weak stock performance, influenced by industry policies and market conditions [2][3][8]. Financial Performance - In the first three quarters of 2025, the company's net profit attributable to shareholders was 112 million yuan, a year-on-year decrease of 45.69% [2]. - The net profit for the third quarter alone was 39.3 million yuan, down 44.51% year-on-year [2]. - The gross margin has further declined to 8.02%, with a net margin of only 1.41%, indicating pressure on profit quality [3]. Market Activity - On February 13, the stock closed at 10.69 yuan, down 1.02%, and hit a 60-day low, with a trading volume of 69.91 million yuan and a turnover rate of 1.12% [1]. - There was a net outflow of 3.72 million yuan from main funds, continuing a trend of net outflows over recent days [4]. - The overall pharmaceutical commercial sector saw a net outflow of 184 million yuan, indicating a weak funding environment that exacerbates selling pressure on individual stocks [5]. Valuation and Technical Indicators - The stock price has fallen below the 60-day moving average, with the MACD histogram turning negative at -0.18, and the KDJ indicator showing an oversold signal with the J line at -4.44 [6]. - The lower support level of the Bollinger Band has shifted to 10.37 yuan, and breaching this level could trigger further technical selling pressure [7]. Industry Environment - The pharmaceutical commercial sector declined by 0.89% due to common industry factors such as deepening centralized procurement and extended medical insurance reimbursement cycles [8]. - Investor sentiment has been cautious ahead of the Spring Festival, leading to reduced positions due to concerns over market volatility during the holiday [8]. Financial Risks - The accounts receivable reached 4.079 billion yuan, accounting for 58.19% of total assets, highlighting significant pressure on cash flow [10]. - Despite efforts to expand the DTP pharmacy business, which saw a revenue increase of 22.81%, it is unlikely to offset the decline in wholesale business in the short term [10]. Future Outlook - The recent stock price breakdown is attributed to weak performance, risk aversion in funding, and technical breakdowns [11]. - Short-term focus should be on the effectiveness of the 10.37 yuan support level and whether first-quarter performance can improve [11]. - While industry policies may drive transformation, the market is more concerned with accounts receivable management and the substantive recovery of profitability [11].

Investment Rating - The investment rating for the pharmaceutical and biotechnology sector is "Outperform the Market" (maintained) [2] Core Insights - The pharmaceutical sector underperformed the market in Q4 2025, with the overall sector down by 9.3% compared to a slight decline of 0.2% in the CSI 300 index. Notably, the pharmaceutical commercial segment showed a positive performance with a 5.3% increase, while other segments like medical services and biological products experienced significant declines [4][8] - The total net asset value of pharmaceutical funds decreased to 358.4 billion yuan, a 9.0% decline quarter-on-quarter. This marks the first time since 2019 that passive pharmaceutical funds (181.8 billion yuan) surpassed active funds (176.5 billion yuan) [4][14] - The overall pharmaceutical holdings across all funds dropped to 7.97%, a decrease of 1.71 percentage points. Active pharmaceutical funds maintained a high concentration with a holding ratio of 97.45% [23] Summary by Sections 1. Market Review - In Q4 2025, the pharmaceutical and biotechnology sector lagged behind the CSI 300 index, with a decline of 9.3%. The chemical pharmaceuticals segment fell by 9.6%, biological products by 12.4%, and medical devices by 10.6% [8] 2. Pharmaceutical Fund Size - As of Q4 2025, the net asset value of pharmaceutical funds was 358.4 billion yuan, down 9.0% from the previous quarter. Active funds accounted for 176.5 billion yuan, a 14.6% decrease, while passive funds reached 181.8 billion yuan, down 2.8% [14] 3. Pharmaceutical Holdings Ratio - The pharmaceutical holdings ratio for all funds was 7.97%, down 1.71 percentage points. Active pharmaceutical funds had a holding ratio of 97.08%, while passive funds had 97.83% [23] 4. Holdings Structure Analysis - The highest sub-sector holding in Q4 2025 was chemical preparations at 37.5%, followed by other biological products at 20.8%. The largest increases in holdings were seen in traditional Chinese medicine (+0.98 percentage points) and chemical preparations (+0.62 percentage points) [29] 5. Additions and Reductions in Holdings - The top three pharmaceutical stocks by the number of funds holding them were Heng Rui Medicine (498 funds), WuXi AppTec (408 funds), and Mindray Medical (204 funds). Notably, Heng Rui Medicine saw a reduction of 236 funds, while Ying En Biological-B experienced an increase of 47 funds [84][88]

最近业绩情况 公司1月16日发布的2025年业绩预告显示预计亏损8500万元，但亏损同比收窄10%，主要因子公司商誉 减值(约6200万元)及业务调整影响。市场对此前跌停反应过度，后续情绪有所缓和。 资金走向 经济观察网国发股份（600538）在2026年2月13日出现逆市上涨，主要受技术面超跌反弹、医药板块情 绪回暖、业绩利空阶段性消化及资金流向变化等因素影响。 股票近期走势 2月9日公司股价因业绩预亏及龙虎榜资金大幅流出跌停(单日跌幅10.05%)，随后连续两个交易日缩量震 荡。截至2月13日，股价短期技术指标进入超卖区间(KDJ的J值降至0.89)，存在修复需求。当日股价低 开高走，收盘报6.75元，涨幅4.81%，收复5日均线(6.614元)，但仍低于20日均线(7.016元)。 行业板块情况 尽管当日上证指数下跌1.26%，医药生物板块跌幅0.78%，但国发股份所属的医药商业板块跌幅收窄至 0.89%，部分资金流向小市值超跌股。公司流通市值仅35.38亿元，易受短期资金扰动。 2月13日主力资金小幅净流入15.19万元，与前一日净流出314.11万元相比呈现回流迹象。但整体成交额 仅1.40亿元，较 ...

Core Insights - China National Pharmaceutical Group (国药股份) is a leading pharmaceutical commercial enterprise, currently holding a 20% stake in Yichang Humanwell, which is expected to contribute approximately 500 million yuan in investment income in 2024 [1] - The company dominates the pharmaceutical direct sales market in Beijing and has a current market capitalization of approximately 22 billion yuan, which is below the reasonable valuation of 26.5 billion yuan, indicating potential undervaluation [1] - For 2024, the company is projected to achieve revenue of 50.597 billion yuan and a net profit attributable to shareholders of 2 billion yuan, with stable operating cash flow [1] - The pharmaceutical industry is influenced by centralized procurement policies, but fluctuations for distribution companies are relatively minor [1] Institutional View - As of February 13, 2026, the comprehensive target price for the stock is 36.49 yuan, indicating a potential upside of 26.35% from the latest stock price, with a forecasted net profit growth of 1.04% year-on-year for 2025 [2] Stock Performance - Over the past week (February 7-13, 2026), the stock price of China National Pharmaceutical Group experienced slight fluctuations, closing at 28.99 yuan on February 13, reflecting a decline of 0.82% during this period, with a volatility of 1.71% [3] - The stock performance was slightly better than the pharmaceutical commercial sector, which saw a decline of approximately 0.55% during the same timeframe [3] - The highest trading volume reached 138 million yuan on February 9, with a turnover rate of 0.44% on February 13, indicating stable market trading [3] - Technically, the stock price has been hovering around the 20-day moving average of 29.12 yuan, with support at 28.67 yuan and resistance at 29.53 yuan [3]

公司持续执行股份回购计划，截至2025年12月累计回购8099万元，同时通过转让财务公司股权优化资产 负债率，这些举措的后续效果值得关注。 行业政策与环境 经济观察网重药控股（000950）近期经营动态与外部合作取得进展，涉及与辉瑞的合作里程碑付款、公 司资产结构优化以及行业政策影响。 近期事件 公司参股子公司药友制药与辉瑞签署全球独家许可协议，已于2026年1月收到首付款1.5亿美元，后续5 亿美元里程碑款的支付进度可能成为市场焦点。 公司状况 医药商业板块受创新药概念及政策预期影响，2025年12月曾出现外资净买入和板块活跃现象，后续行业 动态可能对公司股价形成联动效应。 以上内容基于公开资料整理，不构成投资建议。 ...